5V19
Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy
Summary for 5V19
Entry DOI | 10.2210/pdb5v19/pdb |
Related | 5V24 |
Descriptor | Mitogen-activated protein kinase kinase kinase 5, N-(1-ethyl-1H-pyrazol-4-yl)furan-3-carboxamide (3 entities in total) |
Functional Keywords | transferase, metal-binding, apoptosis, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (Human) |
Cellular location | Cytoplasm: Q99683 |
Total number of polymer chains | 2 |
Total formula weight | 61430.23 |
Authors | Dougan, D.R.,Lawson, J.D.,Lane, W. (deposition date: 2017-03-01, release date: 2017-03-29, Last modification date: 2024-03-06) |
Primary citation | Gibson, T.S.,Johnson, B.,Fanjul, A.,Halkowycz, P.,Dougan, D.R.,Cole, D.,Swann, S. Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy. Bioorg. Med. Chem. Lett., 27:1709-1713, 2017 Cited by PubMed: 28291695DOI: 10.1016/j.bmcl.2017.02.079 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.1 Å) |
Structure validation
Download full validation report